ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
ImmuneOnco Biopharmaceuticals has announced the sale of a 7% equity stake in one of its wholly-owned subsidiaries to Jiaxing Changxin, after market hours on September 13, 2024. This transaction, involving a consideration of RMB 140,000, makes Jiaxing Changxin a connected person to the company, but is classified as a de minimis connected transaction, exempt from requiring shareholder approval. The company retains a 93% stake in the subsidiary, affirming its commitment to transparency and corporate governance standards.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.
